Research and Markets (http://www.researchandmarkets.com/research/5f070e/novo_nordisk_partn) has announced the addition of the "Novo Nordisk Partnering Guide 2008" company profile to their offering.
Provides an in-depth insight into the partnering interests and activities of one of the worlds leading biopharma companies.
This report provides all the information you require to better understand Novo Nordisk and its partnering interests and activities over the past five years.
One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
Using this report, dealmakers will effectively and efficiently determine the suitablility of Novo Nordisk as a prospective partner, their business development objectives, interests and recent partnering activity, key partnering contacts, and partnering contract documents signed with their recent partners.
The report provides a firm basis for initial due diligence into Novo Nordisk as a prospective partner company.
Key benefits
Novo Nordisk Partnering Guide 2008 report provides the user with the following key benefits:
- Detailed company profile of the company
- In-depth marketed and pipeline product activity for the company
- Partnering interests and therapy focus revealed
- Partnering activity since 2000 – number of deals per year
- Partnering activity for 2005-2008
- Activity by deal type
- Activity by phase of development
- Activity by therapeutic area
- List of recent partner companies
- Comprehensive access to actual contracts entered into by the company and its partners*
- Insight into the terms included in a partnering agreement
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
*Subject to being published via regulatory requirements of the Securities Exchange Commission.
Report scope
Novo Nordisk Partnering Guide 2008 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the company, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s approach to partnering.
The Novo Nordisk Partnering Guide 2008 report also provides comprehensive access to available contract documents for the company. Analyzing actual company agreements allows assessment of the following:
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subscontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
- Bigpharma – The Top 50
- Most active bigpharma dealmakers
- Top bigpharma deals – 2000-7
- Submitting Opportunities to Bigpharma such as Novo Nordisk
- Forthcoming bigpharma partnering events
- Novo Nordisk – therapy locator
- Bigpharma Company Profiles
- Figures in report
For more information visit http://www.researchandmarkets.com/research/5f070e/novo_nordisk_partn
Contacts:
Laura Wood
Senior Manager
press@researchandmarkets.com
Fax
from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716
